Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
ISOPTO CARPINE vs MYOTONACHOL
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Pilocarpine, a direct-acting cholinergic agonist, stimulates muscarinic receptors (M3 subtype) in the ciliary muscle and iris sphincter muscle, causing miosis and contraction of the ciliary muscle. This opens the trabecular meshwork and increases aqueous humor outflow facility, reducing intraocular pressure in glaucoma. Also induces accommodation spasm.
Myotonachol (bethanechol chloride) is a direct-acting parasympathomimetic agent that selectively stimulates muscarinic acetylcholine receptors, particularly M3 subtypes, in smooth muscle of the gastrointestinal tract and urinary bladder. It mimics the action of acetylcholine but is resistant to hydrolysis by acetylcholinesterase, leading to increased smooth muscle tone and peristalsis.
FDA: For the treatment of elevated intraocular pressure in patients with primary open-angle glaucoma or ocular hypertension.,Off-label: Emergency reduction of intraocular pressure in acute angle-closure glaucoma, induction of miosis during ocular surgery, diagnosis of Adie's tonic pupil.
FDA-approved: Treatment of acute postoperative and postpartum nonobstructive urinary retention and neurogenic atony of the bladder.,Off-label: Treatment of gastroesophageal reflux disease; management of chronic intestinal pseudo-obstruction; treatment of xerostomia (dry mouth) in Sjögren's syndrome or radiation-induced.
1 to 2 drops of a 1% to 4% solution in the affected eye(s) up to 4 times daily, as needed to reduce intraocular pressure.
25 mg orally three times daily. Maximum dose 100 mg four times daily.
Terminal elimination half-life is approximately 1.4 hours in healthy adults; clinically, this short half-life necessitates frequent dosing for sustained ocular effect.
Terminal elimination half-life: 1.5-2.5 hours (prolonged in renal impairment).
Primarily metabolized by plasma esterases via hydrolysis, with some hepatic metabolism. Half-life ~1-2 hours. Excreted renally as metabolites and unchanged drug.
Bethanechol is primarily metabolized via hydrolysis by plasma esterases (pseudocholinesterases) to inactive metabolites. Minimal hepatic metabolism occurs.
Primarily renal excretion of unchanged drug and metabolites; approximately 80% of a dose is eliminated via urine within 24 hours, with about 20% as unchanged pilocarpine. Biliary/fecal elimination accounts for less than 5%.
Renal: 70-80% unchanged; biliary/fecal: 20-30% as metabolites.
Approximately 30% bound to plasma proteins, mainly albumin.
~30%, bound primarily to albumin.
Approximately 0.5 L/kg, indicating distribution largely into extracellular fluid; clinically, not extensively distributed to tissues.
0.3-0.6 L/kg, indicating distribution into total body water.
Ocular (topical): bioavailability is low due to nasolacrimal drainage and systemic absorption; exact % not well defined but systemic exposure is minimal with recommended ophthalmic dosing.
Oral: 10-20% (extensive first-pass metabolism); Subcutaneous: ~80%; Intravenous: 100%.
No dosage adjustment required for renal impairment; drug is minimally systemically absorbed and renally eliminated.
GFR 30-59 m L/min: 25 mg twice daily. GFR 15-29 m L/min: 25 mg once daily. GFR <15 m L/min: not recommended.
No dosage adjustment required for hepatic impairment; drug is minimally systemically absorbed and primarily metabolized locally.
Child-Pugh A: no adjustment. Child-Pugh B: 25 mg twice daily. Child-Pugh C: not recommended.
Not recommended for use in children due to lack of safety and efficacy data; use only if potential benefit outweighs risk.
0.5-1 mg/kg orally three times daily; maximum 25 mg per dose.
Use with caution in elderly patients due to increased risk of systemic anticholinergic effects (e.g., bradycardia, bronchospasm); consider lower concentration or frequency.
Start at 25 mg twice daily due to increased anticholinergic sensitivity.
None
None
Risk of retinal detachment, especially in patients with pre-existing retinal disease or myopia.,May cause ciliary spasm, brow ache, and induced myopia.,Caution in patients with corneal abrasion or contact lens use due to miosis and accommodation effects.,Bronchospasm risk in patients with asthma or COPD.,Bradycardia, hypotension, and increased GI motility (use caution in peptic ulcer disease, urinary tract obstruction, or Parkinson's disease).,Systemic absorption can cause cholinergic toxicity.
May cause reflex tachycardia due to hypotension; caution in patients with coronary artery disease, bradycardia, or recent myocardial infarction. Increased vagal tone may precipitate asthma attacks; avoid in asthmatics. May cause exacerbation of peptic ulcer disease. Can increase ureteral pressure; avoid in ureteral obstruction. Use cautiously in patients with epilepsy or hyperthyroidism. Monitor for cholinergic crisis (salivation, lacrimation, urination, defecation, emesis).
Hypersensitivity to pilocarpine or any component.,Acute iritis, acute anterior uveitis, or acute inflammatory conditions of the anterior chamber.,Narrow-angle glaucoma (unless considered for emergency treatment under specialist care).,Uncontrolled asthma, COPD, or other bronchospastic conditions.,Severe cardiovascular disease (bradycardia, hypotension, recent MI).,Gastrointestinal or urinary tract obstruction.,Concomitant use with other cholinergic agents due to additive toxicity.
Absolute: Hypersensitivity to bethanechol; mechanical obstruction of the gastrointestinal or urinary tract; recent gastrointestinal anastomosis or bladder surgery; hyperthyroidism; peptic ulcer disease; asthma; epilepsy; Parkinsonism; hypotension; bradycardia; coronary artery disease. Relative: Pregnancy (C); nursing mothers; patients with vagotonia or receiving quinidine or procainamide.
No known food interactions.
Food decreases absorption; take on an empty stomach. Avoid high-fat meals as they may increase side effects. No known specific food interactions.
Insufficient human data. Animal studies: no teratogenicity at ocular doses. Risk cannot be excluded. Avoid in first trimester unless benefit outweighs risk.
Pregnancy Category C. First trimester: Animal studies show fetal resorption and skeletal anomalies at doses 2-3 times the maximum recommended human dose. No adequate human studies. Second trimester: Potential for premature labor due to cholinergic stimulation. Third trimester: Increased risk of uterine hyperstimulation and fetal distress if used for labor induction. Avoid use during pregnancy unless clearly needed.
Limited data; no M/P ratio available. Pilocarpine may suppress lactation via cholinergic effect. Use caution; monitor infant for cholinergic side effects.
Excreted in human milk in low concentrations. M/P ratio not established. Caution advised. Potential for cholinergic adverse effects in the infant (e.g., diarrhea, increased secretions). Use only if benefit outweighs risk.
No established dose adjustments. Monitor IOP closely; pharmacokinetics may be altered due to increased plasma volume and renal clearance. Titrate to effect.
No standard dose adjustments recommended due to limited pharmacokinetic data in pregnancy. However, increased plasma volume and renal clearance may necessitate dose titration based on clinical response. Use lowest effective dose and monitor for maternal cholinergic toxicity.
Isopto Carpine (pilocarpine ophthalmic solution) is a miotic agent used for glaucoma and ocular conditions. It causes miosis and ciliary muscle contraction, reducing intraocular pressure. Onset of miosis is 10–30 minutes, lasting 4–8 hours. Use with caution in patients with retinal detachment, asthma, or bradycardia. Systemic absorption can cause sweating and salivation.
MYOTONACHOL (bethanechol) is a cholinergic agonist used for urinary retention. Monitor for bradycardia and bronchospasm, especially in patients with asthma or cardiac disease. Administer on an empty stomach to reduce nausea. Avoid use in patients with GI obstruction or recent bladder surgery. Atropine should be readily available as an antidote.
Apply pressure to the inner corner of the eye (nasolacrimal occlusion) for 1–2 minutes after instillation to reduce systemic absorption.,Do not touch the dropper tip to any surface to avoid contamination.,Remove contact lenses before use; wait at least 15 minutes before reinserting.,May cause blurred vision, especially at night; avoid driving until vision clears.,Use caution in low-light conditions due to miosis.
Take this medication on an empty stomach, 1 hour before or 2 hours after meals.,Avoid alcohol and caffeine, as they may worsen side effects.,Report symptoms like slow heart rate, wheezing, dizziness, or excessive sweating.,Do not drive or operate heavy machinery until you know how this drug affects you.,If you miss a dose, skip it and take the next dose at the regular time; do not double the dose.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about ISOPTO CARPINE vs MYOTONACHOL, answered by our medical review team.
ISOPTO CARPINE is a Ophthalmic Cholinergic Agonist that works by Pilocarpine, a direct-acting cholinergic agonist, stimulates muscarinic receptors (M3 subtype) in the ciliary muscle and iris sphincter muscle, causing miosis and contraction of the ciliary muscle. This opens the trabecular meshwork and increases aqueous humor outflow facility, reducing intraocular pressure in glaucoma. Also induces accommodation spasm.. MYOTONACHOL is a Cholinergic Agonist that works by Myotonachol (bethanechol chloride) is a direct-acting parasympathomimetic agent that selectively stimulates muscarinic acetylcholine receptors, particularly M3 subtypes, in smooth muscle of the gastrointestinal tract and urinary bladder. It mimics the action of acetylcholine but is resistant to hydrolysis by acetylcholinesterase, leading to increased smooth muscle tone and peristalsis.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between ISOPTO CARPINE and MYOTONACHOL depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of ISOPTO CARPINE is: 1 to 2 drops of a 1% to 4% solution in the affected eye(s) up to 4 times daily, as needed to reduce intraocular pressure.. The standard adult dose of MYOTONACHOL is: 25 mg orally three times daily. Maximum dose 100 mg four times daily.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between ISOPTO CARPINE and MYOTONACHOL in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. ISOPTO CARPINE is classified as Category C. Insufficient human data. Animal studies: no teratogenicity at ocular doses. Risk cannot be excluded. Avoid in first trimester unless benefit outweighs risk.. MYOTONACHOL is classified as Category C. Pregnancy Category C. First trimester: Animal studies show fetal resorption and skeletal anomalies at doses 2-3 times the maximum recommended human dose. No adequate human studies.. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.